Abstract 2258P
Background
Currently, response to cancer treatment cannot be predicted upfront, hampering treatment efficacy. There is a need for effective biomarkers to select patients for optimal treatment. A promising predictive biomarker is response testing on patient-derived organoids (PDOs). For metastatic colorectal cancer (mCRC), it is unclear what drug screening method is optimal and if PDOs predict response for all treatment types.
Methods
Drug screens were performed by exposing 23 PDOs to a concentration range of systemic drugs for 5 days. The following standard mCRC treatments were evaluated: 5-fluorouracil (n = 6), oxaliplatin (n = 14) and irinotecan (n = 10). Drug sensitivity was measured by cell viability and quantified by calculating the area under the curve (AUC). We compared in vitro sensitivity to patient response, evaluated using progression-free survival (PFS) and % change in the size of target lesions on CT scans.
Results
Drug screen methods regarding medium composition (with/without N-acetylcysteine), combination treatment ratios and read-outs were optimized, as they impact the correlation with clinical response. Correlations were seen between PDO response (AUC) and patient response (% change) for all chemotherapies (Spearman r = 0.3-0.6, ns). PFS was evaluable for patients treated with oxaliplatin (n=14). Median PFS of patients with organoids classified as resistant to oxaliplatin-based treatment - based on AUC - was relevantly shorter than for organoids classified as sensitive (3.4 vs 10.1 months, log rank p = 0.07). PDOs from patients previously exposed to chemotherapy showed increased resistance to chemotherapy with a significantly higher AUC (median 0.9 vs 0.4, Mann-Whitney U p = 0.005).
Conclusions
After drug screen optimization, we show that PDO response correlates with patient response to commonly used systemic mCRC treatments. This suggests that PDOs can serve as a predictive biomarker and guide personalized cancer treatment. PDOs adequately reflect prior treatment effect, supporting their use for modeling mCRC. Our findings and optimized screening method will be validated in the ongoing OPTIC trial (NL61668.041.17), to facilitate implementation of PDOs in clinical treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
HUB Organoids.
Disclosure
L. Valkenburg-van Iersel: Financial Interests, Advisory Role, Also travel/accommodations paid or reimbursed: Servier, Pierre Fabre; Financial Interests, Advisory Role: Roche, Amgen. M. Koopman: Financial Interests, Institutional, Advisory Board, advisory board and speaker: Pierre Fabre; Financial Interests, Institutional, Advisory Board: MSD, Bayer; Financial Interests, Institutional, Advisory Board, Advisory Board, speaker: Servier; Financial Interests, Institutional, Invited Speaker: Merck, BMS; Financial Interests, Institutional, Trial Chair: Servier; Financial Interests, Institutional, Research Grant: Servier, Roche, Bayer, Bristol Myers Squibb, Merck, Personal Genomics Diagnostics, Sirtex, Pierre Fabre; Financial Interests, Institutional, Funding: Pierre Fabre, Amgen, Nordic Pharma, Novartis, Merck, Servier, BMS; Non-Financial Interests, Leadership Role, vice-chair of DCCG: Dutch Colorectal Cancer Group; Non-Financial Interests, Advisory Role, Member of KWF scientific board: KWF; Non-Financial Interests, Other, ESMO faculty member for the Gastro-Intestinal Tumours – colorectal cancer: ESMO; Non-Financial Interests, Advisory Role, expert member of committee “regie op registers dure geneesmiddelen” ZINNL; Non-Financial Interests, Advisory Role, CRC expert on Kanker.nl platform for answering online CRC questions of CRC (non) patients: Patient representative organisation (Kanker.nl); Non-Financial Interests, Leadership Role, chair of RWD & DH working group: ESMO; Other, PI of the Dutch Prospective Colorectal Cancer Cohort study: PLCRC project. J.M.L. Roodhart: Financial Interests, Institutional, Advisory Board: Bayer, BMS, Merck-Serono, Pierre Fabre, Servier, Amgen; Financial Interests, Institutional, Funding: HUB Organoids, Cleara Biotech, BMS, Pierre Fabre, Servier; Financial Interests, Institutional, Member of Board of Directors: Foundation Hubrecht Organoid Biobank. All other authors have declared no conflicts of interest.
Resources from the same session
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08